

Metamorphosis (Transfiguration) of Spontaneous Bacterial Peritonitis

Djurkov V^{1*}, Kiprin G¹, Dimitrova E² and Krastev N³

¹Ward of Gastroenterology, University Hospital "Euro hospital", Medical University - Plovdiv, Bulgaria

²Department of Informatics and Statistics, University of Food Technologies, Plovdiv, Bulgaria

³Clinic of Gastroenterology and Hepatology, University Hospital "St. George"- Plovdiv, Bulgaria

Received: 19 June 2020

Accepted: 29 June 2020

Published: 01 July 2020

*Corresponding author:

Ventzeslav Djurkov, Ward of Gastroenterology, University Hospital "Euro hospital", Medical University - Plovdiv, Bulgaria, Tel: +359 32 20 70 15; 20 70 26 int. 451; Mobile: +359897367465; Fax: +359 32 20 70 06, E-mail: vdjurkov@eurohospital.bg

1. Review Article

Nowadays between 30% and 50% of patients with liver cirrhosis die due to bacterial infections [1, 2]. Spontaneous Bacterial Peritonitis (SBP) is a big complication of the severe complication "ascites" in liver cirrhosis [3-5]. SBP is the main cause of death in patients with cirrhosis [2, 6].

SBP does not arise from intraabdominal source which requires surgery [6, 7], but via bacterial translocation of intestinal (monomicrobial) flora in the mesenteric lymph nodes [8]. SBP is observed in 10-15% of all patients with cirrhosis and ascites, but its incidence increases to 29-33% in patients with double increased serum bilirubin and/or creatinine ($>88,4 \mu\text{mol/L}$) [9]. Renal dysfunction is an important predictor of mortality in patients with SBP [10].

The life duration of patients with liver cirrhosis and ascites is now significantly extended [11]. The prolonged survival of patients with cirrhosis and ascites leads to increased incidence of SBP. In 1/4 of the cases SBP occurs in the third year after manifestation of ascites (7-30% per year) [12].

Global trend in the etiology of SBP is the displacement from gram-negative to gram-positive microorganisms [13] (and in naïve patients) [14, 15]. At present, half of the episodes of SBP are caused by gram-positive bacteria [14]. Multidrug-resistant (MDR), extensively drug-resistant and pan drug resistant bacteria are an independent predictive factor of mortality in patients with SBP [16, 17]. The prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US Liver Center is high [18]. The quinolone prophylaxis leads to increasing the proportion of gram-positive microorganisms in the etiology of SBP and the resistance to the empirical treatment [15].

SBP is rarely observed in outpatients, but 26-50% of the episodes of SBP are during hospitalization. Nosocomial infections in SBP are not rare (38.8%) and half (52%) of them are caused by gram-positive bacteria [15, 19] (difficult for treatment).

Nowadays bleeding from oesophageal varices is not the leading predisposing factor for SBP, due to the early antibacterial prophylaxis [20].

Although SBP has been observed in 70-85% of patients with Child-Pugh class C liver cirrhosis [6], today SBP can be observed in 51-68.5% of the patients with cirrhosis in class B [21, 22]. Peritonitis in Child-Pugh class A cirrhosis is probably secondary [23]. MELD score is not related to SBP [24].

The classical (oligo symptomatic) clinical form of SBP and the culture-negative neutrophilic ascites (CNNA) are the most common forms of contemporary ongoing SBP. Fatigue, low grade fever, impaired liver function, encephalopathy [10-50% (1, 25)] and renal dysfunction [in 1/3 of the patients with SBP [26] may be the only symptoms of SBP. The minimal and covered hepatic encephalopathy are rarely diagnosed [27]. The latent (10%) and oligo symptomatic forms of SBP have become more frequent, and fulminant forms are rare - 5% [23, 28]. In over 10L of ascites peritoneal irritation is absent not only in SBP, but in perforative peritonitis as well [29].

Peripheral blood leucocyte count $\geq 11 \times 10^9/l$ and/or MELD ≥ 22 define poor prognosis of SBP [30]. Elevated CRP is however a better diagnostic marker for SBP than leukocytosis [31].

In patients with Ascitic Fluid Total Protein (AFTP) <10g/L the risk of SBP increases tenfold (6). After diuretic treatment AFTP increases [32] and SBP may occur at higher values of AFTP (usually <15g/L) (33, 34). Leukocytes also increase in ascitic fluid after diuretic treatment, but not the polymorpho nuclears (PMNs) [32].

According to IAC (International Ascites Club) the SBP diagnosis is considered to be placed in PMNs>250/mm³ [35], including the cases of CNNA (variant of SBP), as there is no significant difference in mortality between SBP and CNNA [36]. Delayed paracentesis is associated with increased in-hospital mortality in patients with SBP [37]. PMNs in ascitic fluid increase >250/mm³ in gram-negative flora, but it is not clear whether this is the same in gram-positive microorganisms [38]. On the 48th hour from the beginning of a successful empirical treatment PMNs decrease with 25% [33]. The failure of empiric treatment of SBP may be due to antimicrobial resistance or secondary bacterial peritonitis [33]. Persistent SBP is a common complication in patients with SBP and high score in the model for end-stage liver disease [39]. Follow-up create nine level is an important predictive factor of in-hospital mortality in cirrhotic patients with SBP [40].

The ascitic bacterialculturesare rarelypositive (≈40%) [33]. Due to the low concentration of micro organisms in ascitic fluid (1 bacteria/1 ml) [23], even if collected in blood culture broth (≈70%) [33]. Peritoneal fluid cultures rarely alter management in patients with ascites [41].

In negative bacterial cultures and PMNs in ascitic fluid >250/mm³, the isolated bacteria from blood cultures should be considered a causative agent of SBP [42].

Bacter Ascites (BA) (positive bacterialculturesfrom ascitic fluid without PMNs>250/mm³) israrelyobserved- 5%. BA does not needtreatment, but monitor in, if there are no clinical symptoms [33]. At a more advanced stage of cirrhosis BA might progress to SBP.

First-line treatment with cephalosporins in SBP provides poor antibiotic coverage [43]. Third generation cephalosporin's are recommended as first-line treatment for community-acquired SBP in countries with low rates of bacterial resistance [34]. Treatment of nosocomial SBP: carbapenem alone or with daptomycin, vancomycin or linezolid if high prevalence of MDR gram +/- bacteria or sepsis [34].

Albumin should be used in all patients with SBP [33, 34] [? [9, 44, 45]]. Renal dysfunction is the most important predict of mortality in cirrhotic patients with SBP [10].

Primary prophylaxis with norfloxacin in patients with Child-Pugh score ≥9 and serum bilirubin level ≥3mg/dL, with either impaired renal function or hyponatraemia, and AFTP <15g/L is recommended [34].

2. Keywords: Spontaneous bacterial peritonitis; Culture-negative neutrophilic ascites; Child-Pugh classification, Forms of spontaneous bacterial peritonitis

3. Conclusion

In the coming years, serious problems with the diagnosis and treatment of SBP are expected.

References

1. Bunchorntavacul C, Chavalitdhamrong D. Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. *World J Gastroenterol.* 2012; 4:158-68.
2. Christou L, Pappas G, Falagas M. Bacterial infection-related morbidity and mortality in cirrhosis. *Am J Gastroenterol.* 2007; 102: 1510-5.
3. Runyon B. Management of adult patients with ascites due to cirrhosis. *Hepatology.* 2004; 39: 841-56.
4. Gravito-Soares M, Gravito-Soares E, Lopes S, et al. Spontaneous bacterial peritonitis a rare but severe complication of liver cirrhosis. *Eur J Gastroenterol Hepatol.* 2017; 29: 1010-6.
5. Lata J, Stiburek O, Kopacova M. Spontaneous bacterial peritonitis: A severe complication of liver cirrhosis. *World J Gastroenterol.* 2009; 15: 5505-10.
6. Alaniz C, Regel RE. Spontaneous bacterial peritonitis. *P&T.* 2009; 34: 204-10.
7. Koulaouzidis A. Diagnosis of spontaneous bacterial peritonitis. *World J Gastroenterol.* 2011; 17: 1091-4.
8. Berg R. Bacterial translocation. In: *Gut and the Liver.* Ed. H Blum, C Bode, J Bode, R Sartor. Kluwer Academic Publishers. Dordrecht/Boston/London. 1998; 47-60.
9. Terg R, Gadano A, Cartier M, et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis. *Liver Int.* 2009; 29: 415-9.
10. Tandon P, Garcia-Tsao G. Renal dysfunction is the most important predict of mortality in cirrhotic patients with spontaneous bacterial peritonitis. *Clin Gastroenterol.* 2011; 9: 260-5.
11. Kashani A, Landaverde C, Medici V, et al. Fluid retention in cirrhosis: Pathogenesis and management. *QJM.* 2008; 101: 71-85.
12. Reginato TJB, Olivera MJA, Moreira LC, et al. 2011, Characteristics of ascitic fluid from patients with suspected spontaneous bacterial peritonitis. *Sao Paulo Med J;* 129: 315-9.
13. Almeida P, Camargo N, Arenz M, et al. Spontaneous bacterial peritonitis: Impact of microbiological changes. *Arq Gastroenterol.* 2007; 44: 68-72.
14. Piroth L, Pechinot A, Minell A, et al. Bacteria epidemiology and antimicrobial resistance in ascitic fluid: a 2-year retrospective study. *Scand J Infect Dis.* 2009; 41: 847-51.
15. Kim J, Kang CI, Joo EJ, et al. Risk factor of communiti-onset spontaneous bacterial peritonitis caused by fluoroquinolone-resistant *Escherichia coli* in patients with cirrhosis. *Liver Int.* 2013; Nov 5.
16. Alexopoulou A, Vasilieva L, Agiasotelli D, et al. Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia. *World J Gastroenterol.* 2016; 22: 4049-56.
17. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant,

- extensively drug-resistant and pandrug resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2012; 18: 268-81.
18. Tandon P, Delisle A, Topal JE, et al. High prevalence of antibiotic-resistant bacteria infectious among patients with cirrhosis at a US Liver Center. *Clin Gastroenterol Hepatol.* 2012; 10: 1291-8.
 19. Mathurin S, Chapelrt A, Spanevello V, et al. Infection in hospitalized patients with cirrhosis. *Medicina (B Aires).* 2009; 69: 229-38.
 20. Bac D, Swart R, van der Berg JWO, et al. Small bowel function in patients with advanced liver cirrhosis and portal hypertension: Studies on permeability and luminal bacterial overgrowth. *Eur J Gastroenterol Hepatol.* 2012; 5: 383-7.
 21. Riggio O, Angeloni S. Ascitic fluid analysis for diagnosis and monitoring of spontaneous bacterial peritonitis. *World J Gastroenterol.* 2009; 15: 3845-50.
 22. Merin Rodrigues B, Nunez Martinez O, Diaz Sanchez A, et al. Spontaneous bacterial peritonitis in cirrhotic patients over 65 years. *Med Clin (Barc).* 2009; 133: 167-72.
 23. Guarner C, Soriano G. Spontaneous bacterial peritonitis. *Semin Liver Dis.* 1997; 17: 203-17.
 24. Haddan L, Conte TM, Ducratti L, et al. MELD score is not related to spontaneous bacterial peritonitis. *Gastroenterol Res Pract.* 2015; 2015: 27046.
 25. Butterworth R. Complications of cirrhosis III. Hepatic encephalopathy. *J Hepatol.* 2000; 32: 171-80.
 26. Ozmen S, Dursum M, Yaklamaz S, et al. Spontaneous bacterial peritonitis: Pathogenesis, diagnosis and management. *Acta Gastroenterol Belg.* 2006; 69: 276-82.
 27. Quadri A, Ogunwale B, Mullen K, et al. Can we ignore minimal hepatic encephalopathy any longer? *Hepatology.* 2007; 45: 547-8.
 28. Hoefs J, Canawati H, Sapiro F, et al. Spontaneous bacterial peritonitis. *Hepatology.* 1982; 2: 399-407.
 29. Wallerstedt S, Olsson R, Simron M, et al. Abdominal tenderness in ascites patients indicates spontaneous bacterial peritonitis. *Eur J Intern Med.* 2007; 18: 44-7.
 30. Tandon P, Kumar D, Seo YS, et al. The 22/11 risk prediction model: a validated model for predicting 30-day mortality in patients with cirrhosis and spontaneous bacterial peritonitis. *Am J Gastroenterol.* 2013; 108:1473-9.
 31. Cho Y, Park SY, Lee JH, et al. High-sensitivity C-reactive protein level is an independent predictor of poor prognosis in cirrhotic patients with spontaneous bacterial peritonitis. *J Clin Gastroenterol.* 2013; 16.
 32. Hoefs JC. Increase in ascites WBC and protein concentrations during diuresis in patients with chronic liver disease. *Hepatology.* 1981; 1: 249-54.
 33. European Association for the Study of the Liver: EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatol.* 2010; 53: 397-417.
 34. European Association for the Study of the Liver. EASL clinical practice guidelines for management of patients with decompensated cirrhosis. *J Hepatol.* 2018; 30:1-55.
 35. Angeloni S, Leboffe C, Parente A, et al. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. *World J Gastroenterol.* 2008; 14: 2757-62.
 36. Kuiper J, van Buuren H, De Man R. Limited role for routine ascitic culture as a diagnostic tool for spontaneous bacterial peritonitis. *J Hepatol.* 2007; 46: 96.
 37. Kim JJ, Tsukamoto MM, Mathur AK, et al. Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis. *Am J Gastroenterol.* 2014; 109: 1436-42.
 38. Ariza X, Lora-Tamayo J, Castelote J, et al. Polymorphonuclear counts in ascitic fluid and microorganisms producing spontaneous bacterial peritonitis: an under-recognized relationship. *Scand J Gastroenterol.* 2013; 48: 1213-21.
 39. Desasi AP, Reau N, Reddy KG, et al. Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and high score in the model for end-stage liver disease. *Therap Adv Gastroenterol.* 2012; 5: 275-83.
 40. Jun BG, Lee WC, Jang JY, et al. Follow-up creatinine level is an important predictive factor of in-hospital mortality in cirrhotic patients with spontaneous bacterial peritonitis. *J Korean Med Sci.* 2018; 33: e99.
 41. Chinnock B, Gomez R, Hendey G. Peritoneal fluid cultures rarely alter management in patients with ascites. *J Emerg Med.* 2011; 40: 21-4.
 42. Rimola A, Navasa M, Rodes J. Treatment and prophylaxis of spontaneous bacterial peritonitis. In: *Gut and the Liver.* Ed. H Blum, C Bode, J Bode, R Sartori. Kluwer Academic Publishers. Dordrecht/Boston/London. 1998; 354-64.
 43. Novovic S, Semb S, Olsen H, et al. First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage. *Scand J Gastroenterol.* 2012; 47: 212-6.
 44. Narula N, Tsoi K, Marshal JK. Should albumin be used in all patients with spontaneous bacterial peritonitis? *Can J Gastroenterol.* 2011; 25: 373-6.
 45. Bochatay L, Elkrei L, Spahr L, et al. When should we give albumin in patients with cirrhosis. *Rev Med Suisse.* 2015; 11: 1598-601.